|
|
 |
|
Viewing report
|
|
|
|
Opportunities for Proteomics Technology Markets in Europe
Frost & Sullivan, Sep 2005
Low Return on Investment that can Dissuade Potential Entrants in Proteomics Technology Markets Offset by Increasing Public Funding
Proteomic research requires huge capital investments and currently, yields poor revenues. Companies, therefore, infer that the market lifecycle is at a stage where they need to wait before witnessing profits. In addition, pharmaceutical companies are doubtful about adopting this new technology in their drug development pipeline as they are wary of premium pricing. However, public funding institutions are giving importance to this growing biological discipline next to comparative genomics. The proteomics market is considered an emerging area with immense potential. In fact, Governments and federal ministries in the three major countries, namely the United Kingdom, France and Germany, are allocating thematic priorities to nurture the growth of this market. This is likely to result in greater industrialization of this field, which in turn, will boost the confidence of companies to invest in this fast-paced and dynamic arena.
This
Additional Information
Technological Innovation to Propel the Proteomics Market
"The increasing relevance of protein-protein interactions and protein analytics in drug discovery as well as clinical diagnostics has highlighted the importance of proteome research," says the analyst of this study. "The technological shift towards proteome research following the completion of the Human Genome Project combined with technological innovations of instruments is likely to increase the significance of proteome research."
Technological advancements in protein separation technologies and two-dimensional gel electrophoresis are likely to usher in a ubiquitous approach to assess differential protein expressions. Maximum utility of expression proteomics tools in the target discovery phase of drug development is likely to trigger reliable separation and identification of low abundant proteins with poor expression levels. Moreover, the development of matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI) technologies has enlarged the scope of building versatile mass spectrometers, considered the cornerstone of proteomics. The improved mass spectrometers are likely to have enhanced functionalities of automation and compatibility with other proteomics equipment. Another possible trend is the emergence of newer dyes that increase the chances for improved sensitivity.
New Applications Using Proteomics Fostered by Public-private Partnerships
The high impact of emerging technologies such as proteomics is causing radical changes in the fields of drug discovery as well as clinical research and diagnostics. As a result, end users in the European life sciences arena are looking for a complete, integrated solution. The current trend in the markets has been the formation of broad partnerships, as the commercial sector realises that this is one of the best ways of maximizing opportunities in this area since smaller companies can affiliate themselves with larger, more recognized suppliers.
"Besides those between companies, another important collaboration is between companies and academic research units, since such alliances are likely to be potentially very interesting as they are anticipated to be a merger of disciplines," notes the analyst. "This ensures that academic research develops groundbreaking research methodologies, while companies can introduce the technology into possible applications that are likely to boost their business in terms of revenues and in this manner, the uptake of proteomics tools can be encouraged."
Customers who bought this item also bought
Technology Developments in Functional Proteomics (Technical Insights)
Proteomics - Global Strategic Business Report
Proteomics 2003
Post Genome Project Era Proteomics R&D Competition
Proteomics - Technologies, Markets and Companies
BioMed Outsourcing Report - Current Opportunities in the Pharmaceutical and Medical Devices Sectors
Emerging Opportunities in Cancer Nanomedicine
The Future of Personalized Medicine: The Impact of Proteomics on Drug Discovery And Clinical Trial Design
|
|
|
|
